Pleura and Peritoneum最新文献

{"title":"Efficacy of procalcitonin and pentraxin-3 as early biomarkers for differential diagnosis of pleural effusions.","authors":"Anita Sharma,&nbsp;Apurva Agrawal,&nbsp;Girish Sindhwani,&nbsp;Ashish Sharma,&nbsp;Sojit Tomo,&nbsp;Jaykaran Charan,&nbsp;Dharmveer Yadav,&nbsp;Praveen Sharma","doi":"10.1515/pp-2021-0111","DOIUrl":"https://doi.org/10.1515/pp-2021-0111","url":null,"abstract":"<p><strong>Objectives: </strong>Pleural effusion, defined as an abnormal accumulation of fluid in pleural space, can be of two types: transudative and exudative. The primary aim of the study was to assess the predictive accuracy of procalcitonin (PCT) and pentraxin-3 (PTX-3) in comparison to other biochemical markers such as C-reactive protein (CRP), and adenosine deaminase (ADA) in the differential diagnosis of pleural effusions.</p><p><strong>Methods: </strong>A cross-sectional analytical study was conducted on patients with pleural effusion. Multiple comparisons and receiver-operating characteristics (ROC) analyses were made to evaluate the diagnostic significance of biochemical markers.</p><p><strong>Results: </strong>Sixty-six patients with exudative pleural effusion classified as malignant, tuberculous, and parapneumonic effusions (malignant pleural effusion [MPE], tuberculous [TPE], and parapneumonic [PPE]) were included. Significant differences in pleural fluid levels in both PCT (p-value: 0.001) and PTX-3(p-value: 0.001), as well as serum levels of PCT (p-value: 0.001), were observed between the three groups. ROC analysis showed both PTX-3 and PCT having favorable discrimination ability with high sensitivity (≥90%) and specificity to predict PPE from TPE and MPE.</p><p><strong>Conclusions: </strong>Evaluation of serum and pleural fluid PCT and levels of PTX-3 in the pleural fluid may be used as an early biomarker to differentiate the etiology of pleural effusion.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 2","pages":"83-90"},"PeriodicalIF":1.8,"publicationDate":"2021-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2021-0111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39114232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasogastric- vs. percutaneous gastrostomy tube for prophylactic gastric decompression after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.","authors":"Job P van Kooten,&nbsp;Nadine L de Boer,&nbsp;Marjolein Diepeveen,&nbsp;Cornelis Verhoef,&nbsp;Jacobus W A Burger,&nbsp;Alexandra R M Brandt-Kerkhof,&nbsp;Eva V E Madsen","doi":"10.1515/pp-2021-0107","DOIUrl":"https://doi.org/10.1515/pp-2021-0107","url":null,"abstract":"<p><strong>Objectives: </strong>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with postoperative gastroparesis and ileus. In 2015, our practice shifted from using percutaneous gastrostomy tubes (PGT), to nasogastric tubes (NGT) for prophylactic gastric decompression after CRS-HIPEC. This study aimed to compare these methods for length of stay (LOS) and associated complications.</p><p><strong>Methods: </strong>Patients that underwent CRS-HIPEC for peritoneal metastases from colorectal cancer between 2014 and 2019 were included. Cases were grouped based on receiving NGT or PGT postoperatively. Multivariable linear regression determined the independent effect of decompression method on LOS, thereby adjusting for confounders.</p><p><strong>Results: </strong>In total, 179 patients were included in the analyses. Median age was 64 years [IQR:54-71]. Altogether, 135 (75.4%) received a NGT and 44 (24.6%) received a PGT. Gastroparesis occurred significantly more often in the PGT group (18.2 vs. 7.4%, p=0.039). Median LOS was significantly shorter for patients with a NGT (15 [IQR:12-19] vs. 18.5 [IQR:17-25.5], p<0.001). PGT was independently associated with longer LOS in multivariable analysis (Beta=4.224 [95%CI 1.243-7.204]). There was no difference regarding aspiration, pneumonia and postoperative mortality between groups.</p><p><strong>Conclusions: </strong>NGT should be preferred over PGT for gastric decompression after CRS-HIPEC as it is associated with fewer gastroparesis and shorter LOS.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 2","pages":"57-65"},"PeriodicalIF":1.8,"publicationDate":"2021-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2021-0107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39114229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging.","authors":"Marion Larroque,&nbsp;Sandra Mounicou,&nbsp;Olivia Sgarbura,&nbsp;Carine Arnaudguilhem,&nbsp;Lucie Rebel,&nbsp;Cristina Leaha,&nbsp;Pierre-Arnaud Faye,&nbsp;Christine Enjalbal,&nbsp;François Quénet,&nbsp;Brice Bouyssiere,&nbsp;Sébastien Carrere","doi":"10.1515/pp-2020-0149","DOIUrl":"https://doi.org/10.1515/pp-2020-0149","url":null,"abstract":"<p><strong>Objectives: </strong>Platinum salts are commonly used in hyperthermic intraperitoneal chemotherapy (HIPEC) for digestive tract cancer treatment. During HIPEC with oxaliplatin for peritoneal metastases (PMs) treatment, the ovaries are directly exposed to the drug, questioning about ovarian resection and the potential impact of the drug on ovarian functionality, especially in young women of childbearing age. The goal of this work is to understand unwanted damages to the ovaries during HIPEC therapy by the determination of the concentration and distribution of platinum in ovaries in order to address its potential toxicity.</p><p><strong>Methods: </strong>Mass spectrometry imaging techniques, matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and laser ablation inductively coupled plasma mass spectrometry (LA-ICP MS), were used to study the penetration of oxaliplatin in ovaries after HIPEC treatment.</p><p><strong>Results: </strong>MALDI-MS allowed the localization of an oxaliplatin-derivative (<i>m/z</i> 456.2) at the periphery of the ovaries. The quantitative LA-ICP MS maps confirmed the localization of elemental platinum as well as in the central part of ovaries from patients who received a previous platinum salt-based chemotherapy.</p><p><strong>Conclusions: </strong>LA-ICP MS images showed that platinum diffusion was extended in cases of previous systemic treatment, questioning about platinum derivatives gonado-toxicity when combining the two treatments.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 2","pages":"67-74"},"PeriodicalIF":1.8,"publicationDate":"2021-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2020-0149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39114230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer.","authors":"José M Porcel,&nbsp;Paola Murata,&nbsp;Laura Porcel,&nbsp;Silvia Bielsa,&nbsp;Marina Pardina,&nbsp;Antonieta Salud","doi":"10.1515/pp-2020-0152","DOIUrl":"https://doi.org/10.1515/pp-2020-0152","url":null,"abstract":"<p><strong>Objectives: </strong>The prevalence, clinical characteristics and prognosis of pleural effusions (PEs) associated with ovarian cancer (OC) have seldom been addressed systematically, as in the current investigation.</p><p><strong>Methods: </strong>All records of consecutive women with a newly diagnosed OC in our institution over a 13-year period were retrospectively reviewed. Features of PEs on CT scans, pleural fluid analyses, need for definitive therapy of PEs, and the influence of PEs on the overall survival (OS) and progression-free survival (PFS) were evaluated.</p><p><strong>Results: </strong>PEs were observed in 81 (43%) of 189 women with OC, either at presentation of cancer (55 patients) or during the course of the disease (26 patients). The causes of PEs were malignancy (55.5%), unknown (37%), or surgery-related (7.4%). The sensitivity of the cytologic diagnosis of malignant PEs was 79.1%. Sixty percent of malignant PEs required pleurodesis or indwelling pleural catheters for symptomatic relief. The presence of ascites strongly predicted PE development (odds ratio 43.2). Women with PEs fared much worse compared with those without PEs, in terms of OS (26.7 vs. 90.4 months), PFS (9.8 vs. 55.3 months) and tumor recurrences (86.4 vs. 43%). In multivariate analyses, PE remained as a relevant independent variable associated with poor outcome (hazard ratio 9.73 for OS, and 3.87 for PFS). Notably, PEs small enough to preclude tapping, and thus of unknown origin, had a similar bad prognosis as malignant PEs.</p><p><strong>Conclusions: </strong>OC patients with PEs experience decreased survival, including those with trace effusions not amenable to tapping.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 2","pages":"75-81"},"PeriodicalIF":1.8,"publicationDate":"2021-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2020-0152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39114231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trace amounts of irinotecan found in the blood of a surgeon after performing HIPEC: what does it imply?","authors":"Wim Ceelen","doi":"10.1515/pp-2021-0113","DOIUrl":"10.1515/pp-2021-0113","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 2","pages":"47-48"},"PeriodicalIF":1.8,"publicationDate":"2021-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39113799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?","authors":"Guillaume Saint-Lorant,&nbsp;Simon Rodier,&nbsp;Jean-Marc Guilloit,&nbsp;Sophie Ndaw,&nbsp;Mathieu Melczer,&nbsp;Stéphanie Lagadu,&nbsp;Agnès Palix,&nbsp;Raphaël Delépée","doi":"10.1515/pp-2020-0141","DOIUrl":"https://doi.org/10.1515/pp-2020-0141","url":null,"abstract":"<p><strong>Objectives: </strong>Hyperthermic intraperitoneal chemotherapy (HIPEC) is a beneficial surgical technique for patients, but the surgeons are being exposed to cytotoxic drugs. Few biomonitoring studies were led on blood samples in the context of HIPEC. This study aimed to evaluate the surgeon's plasmatic and red blood cell (RBC) contamination by irinotecan, two of its major metabolites and platinum compounds.</p><p><strong>Methods: </strong>HIPEC procedures performed using the coliseum techniques were observed between September 2015 and April 2018 in a French comprehensive cancer center. Irinotecan and its metabolites SN-38 and APC were dosed by UHPLC with a limit of quantification determined at 50 pg/mL. Platinum compounds were dosed by inductively coupled plasma mass spectrometry with a limit of quantification determined at 16 pg/mL.</p><p><strong>Results: </strong>Despite collective and personal protective equipment, 80% of plasma samples were contaminated by irinotecan and 33% by platinum compounds out of 21. The results showed that the surgeon was contaminated after HIPEC and even after a period of HIPEC inactivity. Nineteen percent of plasmatic samples and 45% of RBC samples were contaminated by SN-38, the active metabolite of irinotecan. APC was only found in some RBC samples (33%).</p><p><strong>Conclusions: </strong>Even if this study shows blood contamination by irinotecan, two of its major metabolites (including active SN-38) and platinum compounds both in the plasma and RBC of a surgeon performing the HIPEC procedures, further studies should be performed to confirm these results. Additional studies should be carried out to further investigate the contamination in the context of HIPEC and more broadly in the hospital.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 2","pages":"49-55"},"PeriodicalIF":1.8,"publicationDate":"2021-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2020-0141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39113800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontmatter","authors":"","doi":"10.1515/pp-2021-frontmatter1","DOIUrl":"https://doi.org/10.1515/pp-2021-frontmatter1","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"39 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90876720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current practice and perceptions of safety protocols for the use of intraperitoneal chemotherapy in the operating room: results of the IP-OR international survey.","authors":"Daniel Clerc,&nbsp;Martin Hübner,&nbsp;K R Ashwin,&nbsp;S P Somashekhar,&nbsp;Beate Rau,&nbsp;Wim Ceelen,&nbsp;Wouter Willaert,&nbsp;Naoual Bakrin,&nbsp;Nathalie Laplace,&nbsp;Mohammed Al Hosni,&nbsp;Edgar Luis Garcia Lozcano,&nbsp;Sebastian Blaj,&nbsp;Pompiliu Piso,&nbsp;Andrea Di Giorgio,&nbsp;Giuseppe Vizzelli,&nbsp;Cécile Brigand,&nbsp;Jean-Baptiste Delhorme,&nbsp;Amandine Klipfel,&nbsp;Rami Archid,&nbsp;Giorgi Nadiradze,&nbsp;Marc A Reymond,&nbsp;Olivia Sgarbura","doi":"10.1515/pp-2020-0148","DOIUrl":"10.1515/pp-2020-0148","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the risk perception and the uptake of measures preventing environment-related risks in the operating room (OR) during hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC).</p><p><strong>Methods: </strong>A multicentric, international survey among OR teams in high-volume HIPEC and PIPAC centers: Surgeons (Surg), Scrub nurses (ScrubN), Anesthesiologists (Anest), Anesthesiology nurses (AnesthN), and OR Cleaning staff (CleanS). Scores extended from 0-10 (maximum).</p><p><strong>Results: </strong>Ten centers in six countries participated in the study (response rate 100%). Two hundred and eleven responses from 68 Surg (32%), 49 ScrubN (23%), 45 Anest (21%), 31 AnesthN (15%), and 18 CleanS (9%) were gathered. Individual uptake of protection measures was 51.4%, similar among professions and between HIPEC and PIPAC. Perceived levels of protection were 7.57 vs. 7.17 for PIPAC and HIPEC, respectively (p<0.05), with Anesth scoring the lowest (6.81). Perceived contamination risk was 4.19 for HIPEC vs. 3.5 for PIPAC (p<0.01). Information level was lower for CleanS and Anesth for HIPEC and PIPAC procedures compared to all other responders (6.48 vs. 4.86, and 6.48 vs. 5.67, p<0.01). Willingness to obtain more information was 86%, the highest among CleanS (94%).</p><p><strong>Conclusions: </strong>Experience with the current practice of safety protocols was similar during HIPEC and PIPAC. The individual uptake of protection measures was rather low. The safety perception was better for PIPAC, but the perceived level of protection remained relatively low. The willingness to obtain more information was high. Intensified, standardized training of all OR team members involved in HIPEC and PIPAC is meaningful.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 1","pages":"39-45"},"PeriodicalIF":1.8,"publicationDate":"2021-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2020-0148","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39149250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and pleurodesis outcome in patients with malignant pleural effusion - a systematic review.","authors":"Maged Hassan, Elinor Harriss, Rachel M Mercer, Najib M Rahman","doi":"10.1515/pp-2020-0147","DOIUrl":"10.1515/pp-2020-0147","url":null,"abstract":"<p><p>Malignant pleural effusion (MPE) is a common condition that presents with progressive breathlessness. Long term solutions are often required due to recurrence of effusion after simple drainage. Pleurodesis is one of the main options resorted to for long term control of MPE. There is data to suggest there may be a survival benefit for patients with MPE who achieve successful pleurodesis. A systematic review was carried out to explore this correlation and results suggest that there could be a survival difference according to pleurodesis outcome in patients with MPE. Fifteen studies (reported in 13 papers) were included; 13 (86.6%) of the studies showed survival difference in favour of pleurodesis success. The median [interquartile range] difference in survival between the two groups among the different studies was five [3.5-5.8] months. Most of the included studies suffered moderate to severe risk of bias and, thus, large prospective studies of patients undergoing pleurodesis are required to ascertain this effect.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 1","pages":"1-5"},"PeriodicalIF":1.4,"publicationDate":"2021-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39149247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Priorities, actions and risks in the COVID-19 pandemic: a flash SoMe survey among surgical oncologists.","authors":"Delia Cortés-Guiral,&nbsp;Olivia Sgarbura,&nbsp;Mohammad Alyami,&nbsp;Kazuhiro Yoshida,&nbsp;Yuichiro Doki,&nbsp;Hironori Ishigami,&nbsp;Fabian Grass,&nbsp;Martin Hübner","doi":"10.1515/pp-2020-0142","DOIUrl":"https://doi.org/10.1515/pp-2020-0142","url":null,"abstract":"<p><strong>Objectives: </strong>Corona virus-induced disease 19 (COVID-19) pandemic has globally affected the surgical treatment of cancer patients and has challenged the ethical principles of surgical oncologists around the world. Not only treatment but also diagnosis and follow-up have been disrupted.</p><p><strong>Methods: </strong>An online survey was sent through Twitter and by the surgical societies worldwide. The survey consisted of 29 closed-ended questions and was conducted over a period of 24 days beginning in March 26, 2020.</p><p><strong>Results: </strong>Overall, 394 surgical oncologists from 41 different countries answered the questionnaire. The predominant guiding principle was \"saving lives\" 240 (62%), and the different aspects of lock-down found hence large support (mean 7.1-9.3 out of 10). Shut-down of elective surgery and modification of cancer care found a mean support of 7.0 ± 3.0 and 5.8 ± 3.1, respectively. Modification of cancer care longer than two weeks was considered unacceptable to 114 (29%) responders. Hundred and fifty six (40%) and 138 (36%) expect \"return to normal\" beyond six months for surgical practice and cancer care, respectively.</p><p><strong>Conclusions: </strong>Surgical oncologists show strong and long-lasting support for lock-down measures aiming to save lives. The impact of the pandemic on surgical oncology is perceived controversially, but the majority was forced already now to accept what is inacceptable for many of their colleagues.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"6 1","pages":"7-12"},"PeriodicalIF":1.8,"publicationDate":"2021-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2020-0142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39149248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}